Xenon Pharmaceuticals
(NASDAQ) XENE
Xenon Pharmaceuticals Financials at a Glance
Market Cap
$6.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$383.17M
EPS (TTM)
-$4.70
P/E Ratio
-14.87
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$69.94
Volume
898,024.338
Open
$70.47
Price
$69.94
Volume
898,024.338
Open
$70.47
Previous Close
$69.95
Daily Range
$69.52 - $72.66
52-Week Range
$30.00 - $72.66
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$69.94
Volume
898,024.338
Open
$70.47
Previous Close
$69.95
Daily Range
$69.52 - $72.66
52-Week Range
$30.00 - $72.66
Estimated Earnings Date
Aug 10, 2026
XENE News
XENE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Xenon Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
370
CEO
Ian C. Mortimer, MBA
Website
www.xenon-pharma.comHeadquarters
Burnaby, BC V5G 4W8, CA
XENE Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-49.23%
Return on Capital
-63.26%
Return on Assets
-27.63%
Earnings Yield
-6.72%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$6.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
96.67M
Volume
898.02K
Avg. Volume
1.36M
Financials (TTM)
Gross Profit
-$78.30M
Operating Income
-$412.66M
EBITDA
-$399.03M
Operating Cash Flow
-$306.36M
Capital Expenditure
-$889.00K
Free Cash Flow
-$307.25M
Cash & ST Invst.
$1.09B
Total Debt
$7.49M
Xenon Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
$6.76BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$21.40M
N/A
Employees
316
N/A
Net Income
-$102.30M
-57.3%
EBITDA
-$111.74M
-55.0%
Quarterly Fundamentals
Total Cash
$1.09B
+99.2%
Total Debt
$7.49M
-13.6%
Accounts Receivable
$1.17M
-86.5%
Inventory
$0.00
N/A
Long Term Debt
$5.93M
-18.7%
Short Term Debt
$1.56M
+13.0%
Return on Assets
-27.63%
N/A
Return on Invested Capital
-30.64%
N/A
Free Cash Flow
-$89.03M
-44.3%
Operating Cash Flow
-$88.90M
-44.2%